Ziihera (zanidatamab-hrii)
Approved
HER2-targeted bispecific antibody approved in its first indication, for HER2-positive (IHC 3+) biliary tract cancer in the US, China, Europe and Canada.
Learn more
Zymeworks
Biotechnology & Life SciencesNasdaq: ZYMEVancouver, BC
Vancouver-headquartered biotechnology company developing multifunctional antibody-based biotherapeutics, including bispecifics and antibody-drug conjugates, and licensing them to partners.
Canadian innovation builds a brighter tomorrow.
About
Source: zymeworks.comZymeworks describes itself as a royalty-driven biotechnology company managing a portfolio of healthcare assets and developing a diverse pipeline of novel, multifunctional biotherapeutics, built on nine proprietary platforms for antibody-drug conjugates and multispecific antibodies. Its corporate head office is in Vancouver, though its FY2025 SEC filing lists a Delaware principal executive office following reincorporation.
Ziihera (zanidatamab-hrii) holds regulatory approvals for HER2-positive (IHC 3+) biliary tract cancer in the United States, China, Europe and Canada. sec.gov
J&J Innovative Medicine initiated multiple Phase 3 trials of pasritamig in castration-resistant prostate cancer, announced September 2025. sec.gov
Earned $69.9 million in FY2025 from milestone payments, an option fee and a research extension fee across collaborations with BMS, GSK, Daiichi Sankyo and J&J. sec.gov
Lists its corporate head office at 114 East 4th Avenue, Vancouver; note its FY2025 filing gives a Delaware address as principal executive offices after reincorporation. zymeworks.com
Products & Services
Company site: zymeworks.comProducts Zymeworks publishes on its own site. Each card links to the page it was taken from.
Pasritamig
Clinical development
Programme in clinical development, with J&J Innovative Medicine having initiated multiple Phase 3 trials in castration-resistant prostate cancer.
Learn morePartnerships
Publicly announced partnerships.
Johnson & Johnson Innovative Medicine
Initiated multiple Phase 3 trials of pasritamig in castration-resistant prostate cancer, announced September 2025.
People
Sourced from the company's own pages or announcements.
Kenneth Galbraith
Chair & Chief Executive Officer
Kristin Stafford
Chief Financial Officer
Paul Moore
Chief Scientific Officer
Sabeen Mekan
Senior Vice President and Chief Medical Officer
Technology Focus
Company site: zymeworks.comTerms the company uses about its own work.
Bispecific antibodiesAntibody-drug conjugatesMultifunctional biotherapeuticsAzymetric platformHER2-targeted therapyRoyalty-driven asset portfolio
Similar Companies
Other companies in Biotechnology & Life Sciences.
